Contract development and manufacturing organizations (CDMOs) and biopharmaceutical companies are facing shortages in capacity for production of clinical trial material. Even as large-volume commercial biofilling capacity has increased significantly since the beginning of the pandemic, drug developers are forced to use inefficient and risky filling methods that leave them with unmet demand. John Harmer (Cytiva’s strategic initiatives leader for aseptic filling) addressed the need for flexibility and capacity for CDMOs and their clients by introducing two gloveless robotic isolator technology…